Correction to: Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management.

Autor: Kümpfel, Tania, Giglhuber, Katrin, Aktas, Orhan, Ayzenberg, Ilya, Bellmann-Strobl, Judith, Häußler, Vivien, Havla, Joachim, Hellwig, Kerstin, Hümmert, Martin W., Jarius, Sven, Kleiter, Ingo, Klotz, Luisa, Krumbholz, Markus, Paul, Friedemann, Ringelstein, Marius, Ruprecht, Klemens, Senel, Makbule, Stellmann, Jan-Patrick, Bergh, Florian Then, Trebst, Corinna
Předmět:
Zdroj: Journal of Neurology; Jun2024, Vol. 271 Issue 6, p3702-3707, 6p
Abstrakt: This correction notice addresses mistakes in Table 1 and Table 2 of an article titled "Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management" published in the Journal of Neurology. The corrected tables are provided in the notice. Table 1 includes recommendations on preventive immunotherapies in NMOSD, while Table 2 presents data from trials on NMOSD treatment. The document provides a table summarizing the results of various immunotherapies for NMOSD treatment, including rituximab, inebilizumab, eculizumab, ravulizumab, and satralizumab. The table presents the number of relapses experienced by patients in each treatment group, along with hazard ratios and confidence intervals for comparison. [Extracted from the article]
Databáze: Complementary Index
Externí odkaz: